MCL Literature Feed

Long-term follow-up (37.2 months) in Japanese relapsed/refractory MCL patients shows the ibrutinib-venetoclax combination yields durable complete responses (83% CR), high MRD negativity, and a manageable safety profile.

This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.

The Japanese PMDA has approved the BTK inhibitor acalabrutinib for treating mantle cell lymphoma, providing a new therapeutic option for patients in Japan.

This study evaluates the novel, chemotherapy-free combination of PI3Ki copanlisib and BCL2i venetoclax as a new targeted therapy for patients with relapsed/refractory mantle cell lymphoma.

This large real-world study confirms brexucabtagene autoleucel's high efficacy (91% ORR, 63% 1-yr PFS) in R/R MCL, supporting its standard-of-care role and suggesting earlier use improves outcomes.

This long-term Italian study confirms poor outcomes for allo-HSCT in relapsed/refractory MCL (27% 3-year PFS), with no survival benefit if not in complete remission pre-transplant.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

In a US community setting, real-world data shows MCL patients on zanubrutinib had significantly longer treatment duration and adherence compared to acalabrutinib and ibrutinib, suggesting better persistence.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.

Single-cell analysis reveals pre-existing minor clones with unique mutations drive relapse, explaining patient-specific progression and the need to target intratumoral heterogeneity at diagnosis.

ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.

Ibrutinib can cause rare but severe hepatic subcapsular hematomas in relapsed MCL; ultrasound is a key tool for early diagnosis and monitoring of this bleeding complication.

BRG1-driven suppression of ferroptosis is a key mechanism of BTKi resistance in MCL, and pharmacologic BRG1 inhibition restores BTKi sensitivity, suggesting a new combination therapy.

This case series reports fatal Hepatitis B reactivation with ibrutinib and breakthrough reactivation on zanubrutinib despite prophylaxis, highlighting the need for vigilant HBV monitoring with all BTKis.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

Genomic analysis of MCL treated sequentially with BTKi and venetoclax identifies specific copy number alterations (e.g., 9p21.3 deletion) as novel biomarkers for primary and acquired resistance.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

M2-polarized macrophages drive ibrutinib resistance via the CXCL5/CXCR2 axis; a CXCR2 inhibitor re-sensitizes MCL cells, suggesting a novel combination therapy to overcome BTKi resistance.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This first reported case of composite MCL and T-cell prolymphocytic leukemia highlights the diagnostic challenge of co-existing lymphoid malignancies, where an indolent T-PLL clone was present for years before diagnosis.

This MZL case identifies BTK C481S and PLCG2 D334H co-mutations driving zanubrutinib resistance, a mechanism highly relevant to BTKi failure and subsequent treatment strategies in relapsed MCL.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.